MV4;11 |
childhood B-cell myelomonocytic acute leukaemia (MLL/AF4) |
1.5 ± 1 |
THP-1 |
acute monocytic leukaemia (MLL/AF9) |
4 ± 2 |
KASUMI-1 |
acute myeloid leukaemia with t(8;21) translocation (AML1-ETO) |
0.8 ± 1 |
NALM-17 |
Pre B-blast ALL |
8 ± 4 |
TOM-1 |
Ph1-positive acute lymphoblastic leukaemia (ALL) |
3 ± 5 |
REH |
adult acute lymphoblastic leukaemia (ALL) |
9 ± 4 |
SD-1 |
Epstein-Barr virus immortalised Ph-1 positive ALL |
8 ± 3 |
NALM-6 |
pre-B acute lymphoblastic leukaemia (t(5; 12)(q33; p13)) |
8 ± 3 |
NOMO-1 |
acute monocytic leukaemia (MLL/AF9) |
3 ± 3 |
SEMKH2 |
acute monocytic leukaemia (MLL/AF9) |
2 ± 2 |
RS4;11 |
acute monocytic leukaemia (MLL/AF4) |
2 ± 2 |
KOCL-45 |
acute monocytic leukaemia (MLL/AF4) |
10 ± 5 |
U937 |
leukaemic monocytic lymphoma |
5 ± 3 |
PL21 |
acute promyelolytic leukaemia |
10 ± 5 |
SUPB-15 |
Ph+ childhood B-cell ALL |
11 ± 4 |
K-562 |
erythroleukaemia CML blast (Bcr-ABL) |
>20 |